You usually provide good information and insight. Occasionally, however, you go off the deep end and make no sense. The Majority shareholder, Al Mann, has also seen the value of its initial investment 11 years ago diluted. How many biotechs haven't issued more stock to stay alive???? Equally important, would MannKind even be alive now if that Majority shareholder hadn't pumped in more of his own money after the initial investment? He not only lent money to the company, he also bought more equity in order to make subsequent stock offerings more palatable. And speaking of "destroying minority shareholder value," how does that happen without the majority shareholder losing even more.
Bottom line, your comment that the majority shareholder is faring far better than minority shareholders is complete and utter nonsense.
I completely agree that Matt should be sent ALONE, if they are going to send anyone. I cringe every time Hakan opens his mouth. As for clearing up one thing or the other, or reiterating something, I'm tired of that as well. The timing for the new applications, how the converts are going to be dealt with, etc, have been discussed ad nauseam. Sometimes the answer comes out clearly, sometimes less so, depends on who's speaking unfortunately, but, I think we all know the answers. So, enough.
It's important to also keep in mind that a drug company doing a superiority post-marketing study is like a lawyer asking a question. That is, never ask a question to which you don't know that answer. In other words, Sanofi already knows what the study is going to show, or else it wouldn't be doing it.